Dana-Farber Cancer Institute has secured state approval to construct a new proton therapy center on its Longwood Medical Campus. The planned facility represents a $50 million investment and will introduce advanced proton beam technology to the institute’s cancer treatment offerings.
The approval marks a significant milestone for Dana-Farber as it expands its capabilities in precision cancer therapy. Proton therapy is recognized for its ability to target tumors with high accuracy, potentially reducing side effects compared to traditional radiation treatments.
The new center will be located within Dana-Farber’s main campus in the Longwood Medical area, further strengthening the institute’s presence in Boston’s renowned medical district. The addition of proton therapy aligns with Dana-Farber’s commitment to providing state-of-the-art care to its patients.
Once operational, the proton therapy center is expected to enhance treatment options for patients requiring advanced radiation therapy. The investment underscores the ongoing demand for innovative cancer treatment technologies in Massachusetts and the broader region.
